KalVista Pharmaceuticals (KALV) Financial Statements

618 Followers

KalVista Pharmaceuticals Financial Overview

KalVista Pharmaceuticals's market cap is currently $1.37B. The company's EPS TTM is $-0.92; its P/E ratio is -37.98; KalVista Pharmaceuticals is scheduled to report earnings on March 17, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Apr 25	Apr 24	Apr 23	Apr 22
Income Statement
Total Revenue	$ 73.62M	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 67.54M	$ 0.00	$ -86.17M	$ 0.00	$ 0.00
Operating Income	$ -171.84M	$ -188.00M	$ -140.44M	$ -110.87M	$ -96.61M
EBITDA	$ -170.38M	$ -173.33M	$ -134.28M	$ -94.37M	$ -80.75M
Net Income	$ -164.29M	$ -183.44M	$ -126.64M	$ -92.91M	$ -82.34M
Balance Sheet
Cash & Short-Term Investments	$ 300.21M	$ 187.65M	$ 210.40M	$ 149.38M	$ 166.20M
Total Assets	$ 335.38M	$ 250.77M	$ 235.40M	$ 183.20M	$ 203.88M
Total Debt	$ 151.57M	$ 6.31M	$ 7.32M	$ 8.23M	$ 8.19M
Net Debt	$ -77.77M	$ -92.34M	$ -24.47M	$ -48.01M	$ -22.54M
Total Liabilities	$ 338.09M	$ 155.38M	$ 28.82M	$ 22.18M	$ 18.79M
Stockholders' Equity	$ -2.71M	$ 95.39M	$ 206.58M	$ 161.03M	$ 185.09M
Cash Flow
Free Cash Flow	$ -83.33M	$ -153.34M	$ -89.67M	$ -76.46M	$ -79.06M
Operating Cash Flow	$ -81.62M	$ -152.91M	$ -89.23M	$ -75.26M	$ -78.13M
Investing Cash Flow	$ 18.68M	$ 91.02M	$ -84.72M	$ 41.41M	$ 57.86M
Financing Cash Flow	$ 162.64M	$ 159.73M	$ 150.71M	$ 58.12M	$ 1.58M

Currency in USD

KalVista Pharmaceuticals Earnings and Revenue History

Income Statement >

KalVista Pharmaceuticals Debt to Assets

Balance Sheet >

KalVista Pharmaceuticals Cash Flow

Cash Flow >

KalVista Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >